Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06576037 · ClinicalTrials.gov registry record · Phase 1

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

A Phase 1 study of Solid Tumor, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
128
Enrollment target
1
Study location

NCT06576037 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 128 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06576037, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
128 participants
Enrollment target
1
Study location

Study Summary

An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.

Conditions Studied

Solid Tumor

Interventions

  • DRUG Bevacizumab
  • DRUG Leucovorin
  • DRUG Oxaliplatin
  • DRUG CBP-1019
  • DRUG 5-FLUOROURACIL

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2024-10-31
Est. Completion 2029-06-01
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06576037

The ClinicalTrials.gov registry entry for NCT06576037 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (42% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT06576037 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06576037 about?

NCT06576037 is a clinical study titled "Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin". An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.

What is the current status of trial NCT06576037?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2024-10-31. Estimated completion is 2029-06-01.

What conditions does trial NCT06576037 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT06576037?

The interventions under investigation include: Bevacizumab (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), CBP-1019 (DRUG), 5-FLUOROURACIL (DRUG).

Who is sponsoring clinical trial NCT06576037?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06576037 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.